This expansion may pulverize the anode, resulting in poor performance. To fix this problem scientists looked into varying the dimensionality of the Si. Many studies have been developed in Si nanowires, Si tubes as well as Si sheets. As a result, composite hierarchical Si anodes have become the major technology for future applications in Lithium Ion Batteries. In the early 2020s technology is reaching commercial levels with factories being built for mass production of anodes in the United States. Furthermore, metallic Lithium is another possible candidate for the anode. It boasts a higher specific capacity than Silicon, however, does come with the drawback of working with the highly unstable metallic lithium. Similarly to graphite anodes, dendrite formation is another major limitation of metallic lithium, with the solid electrolyte interphase being a major design challenge. In the end, if stabilized, metallic lithium would be able to produce batteries that hold the most charge, while being the lightest. Mechanical Properties
A common failure mechanism of batteries is mechanical shock, which breaks either the electrode or the system’s container, leading to poor conductivity and electrolyte leakage. However, the relevance of mechanical properties of electrodes goes beyond the resistance to collisions due to its environment. During standard operation, the incorporation of ions into electrodes leads to a change in volume. This is well exemplified by Si electrodes in Lithium-ion batteries expanding around 300% during lithiation. Such change may lead to the deformations in the lattice and, therefore stresses in the material.
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth.The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017. Medical uses
In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. when already being treated with saxagliptin and dapagliflozin. References
External links
"Dapagliflozin propanediol". Drug Information Portal. U.S. National Library of Medicine. "Saxagliptin". Drug Information Portal. U.S. National Library of Medicine. "Dapagliflozin". MedlinePlus. "Saxagliptin". MedlinePlus.